Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…
The type 2 diabetes (T2D) therapy market is forecast to expand through 2032, supported by polypharmacy and growing use of later-line therapies; however, loss of exclusivity for several key T2D…
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…
The rising rates of antimicrobial resistance (AMR) have created an emergent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Since the emergence of the…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three vascular endothelial growth factor (VEGF) inhibitors: Roche / Genentech / Chugai’s Avastin, Roche /…
Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…
Regional Forecast is an add on offering from Clarivate’s Company & Drugs (C&D) that renders extended coverage of existing C&D proprietary data. With increasing demand to analyze the data in much…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…
Clarivate Epidemiology’s coverage of hospital-treated gram-negative infections (HT-GNIs) comprises epidemiological estimates of nine types of infections: urinary tract infections, bloodstream…
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…